{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:15:08Z","timestamp":1793967308553,"version":"4.8.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["400167\/2016-6"],"award-info":[{"award-number":["400167\/2016-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["400167\/2016-6"],"award-info":[{"award-number":["400167\/2016-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/06680-4"],"award-info":[{"award-number":["2017\/06680-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","award":["FT130101648"],"award-info":[{"award-number":["FT130101648"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008353","name":"Funda\u00e7\u00e3o de Apoio ao Ensino, Pesquisa e Assist\u00eancia do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["1901\/2017"],"award-info":[{"award-number":["1901\/2017"]}],"id":[{"id":"10.13039\/501100008353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ocular toxoplasmosis is the leading cause of posterior uveitis worldwide. We conducted an observational study of 262 consecutive individuals (n\u2009=\u2009344 eyes) with ocular toxoplasmosis who were followed over a 34-month period. Most subjects were\n                    <jats:italic>T. gondii<\/jats:italic>\n                    IgG\u2009+\u2009\/IgM- (n\u2009=\u2009242; 92.4%; 317 eyes), and 140 eyes (40.7%) had active lesions. For eyes in which retinal lesions were active at recruitment and best-corrected visual acuity (BCVA) could be measured (n\u2009=\u2009133), 21.0% (n\u2009=\u200928) remained blind (BCVA below 20\/400) after inflammation resolved. In these eyes, atypical ocular toxoplasmosis (OR 4.99; 95% CI 1.14\u201322.85;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0330), macular lesion (OR 9.95; 95% CI 2.45\u201347.15;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0019) and any complication (OR 10.26; 95% CI 3.82\u201330.67;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) were associated with BCVA below 20\/200. For eyes with only inactive lesions at recruitment and BCVA measured (n\u2009=\u2009178), 28.1% (n\u2009=\u200950) were blind. In these eyes, having at least one lesion larger than one disc-diameter (OR 6.30; 95% CI 2.28\u201322.46;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0013) and macular lesion (OR 5.69; 95% CI 2.53\u201313.54;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) were associated with BCVA below 20\/200. Older age (OR 1.02; 95% CI 1.00\u20131.05;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0493) and active disease at presentation (OR 4.74; 95% CI 1.95\u201312.91;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0011) were associated with recurrences. Additional clinical attention should be directed towards patients with risk factors for poor visual outcome.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-82830-z","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T06:08:10Z","timestamp":1612418890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Clinical manifestations and visual outcomes associated with ocular toxoplasmosis in a Brazilian population"],"prefix":"10.1038","volume":"11","author":[{"given":"Sigrid","family":"Arruda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara R.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny M.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Moreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Murilo W.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Rubens","family":"Belfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o M.","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"82830_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/CMR.05013-11","volume":"25","author":"F Robert-Gangneux","year":"2012","unstructured":"Robert-Gangneux, F. & Dard\u00e9, M. L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin. Microbiol. Rev. 25, 264\u2013296 (2012).","journal-title":"Clin. Microbiol. Rev."},{"key":"82830_CR2","first-page":"1","volume":"137","author":"GN Holland","year":"2004","unstructured":"Holland, G. N. Ocular toxoplasmosis: A global reassessment. Part II: Disease manifestations and management. Am. J. Ophthalmol. 137, 1 (2004).","journal-title":"Am. J. Ophthalmol."},{"key":"82830_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1442-9071.2012.02838.x","volume":"41","author":"NJ Butler","year":"2013","unstructured":"Butler, N. J., Furtado, J. M., Winthrop, K. L. & Smith, J. R. Ocular toxoplasmosis II: Clinical features, pathology and management. Clin. Exp. Ophthalmol. 41, 95\u2013108 (2013).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"82830_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1442-9071.2012.02821.x","volume":"41","author":"JM Furtado","year":"2013","unstructured":"Furtado, J. M., Winthrop, K. L., Butler, N. J. & Smith, J. R. Ocular toxoplasmosis I: Parasitology, epidemiology and public health. Clin. Exp. Ophthalmol. 41, 82\u201394 (2013).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"82830_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1017\/S0031182012000765","volume":"139","author":"JP Dubey","year":"2012","unstructured":"Dubey, J. P., Lago, E. G., Gennari, S. M., Su, C. & Jones, J. L. Toxoplasmosis in humans and animals in Brazil: High prevalence, high burden of disease, and epidemiology. Parasitology 139, 1375\u20131424 (2012).","journal-title":"Parasitology"},{"key":"82830_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/09273948.2015.1132741","volume":"25","author":"D Gonzalez-Fernandez","year":"2017","unstructured":"Gonzalez-Fernandez, D., Nascimento, H., Nascimento, C., Muccioli, C. & Belfort, R. Jr. Uveitis in Sao Paulo, Brazil: 1053 new patients in 15 months. Ocul. Immunol. Inflamm. 25, 382\u2013387 (2017).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"82830_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/09273948.2018.1484494","volume":"27","author":"A Schlaen","year":"2019","unstructured":"Schlaen, A. et al. Regional differences in the clinical manifestation of ocular toxoplasmosis between the center and northeast of Argentina. Ocul. Immunol. Inflamm. 27, 722\u2013730 (2019).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"82830_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.survophthal.2011.07.002","volume":"57","author":"JM Furtado","year":"2012","unstructured":"Furtado, J. M. et al. Causes of blindness and visual impairment in Latin America. Surv. Ophthalmol. 57, 149\u2013177 (2012).","journal-title":"Surv. Ophthalmol."},{"key":"82830_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3109\/09273948.2011.582220","volume":"19","author":"A de-la-Torre","year":"2011","unstructured":"de-la-Torre, A., Gonz\u00e1lez-L\u00f3pez, G., Montoya-Guti\u00e9rrez, J. M., Mar\u00edn-Arango, V. & G\u00f3mez-Mar\u00edn, J. E. Quality of life assessment in ocular toxoplasmosis in a Colombian population. Ocul. Immunol. Inflamm. 19, 262\u2013266 (2011).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"82830_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0161-6420(02)00990-9","volume":"109","author":"LE Bosch-Driessen","year":"2002","unstructured":"Bosch-Driessen, L. E., Berendschot, T. T., Ongkosuwito, J. V. & Rothova, A. Ocular toxoplasmosis: Clinical features and prognosis of 154 patients. Ophthalmology 109, 869\u2013878 (2002).","journal-title":"Ophthalmology"},{"key":"82830_CR11","doi-asserted-by":"publisher","first-page":"e0004685","DOI":"10.1371\/journal.pntd.0004685","volume":"10","author":"AL Aleixo","year":"2016","unstructured":"Aleixo, A. L., Curi, A. L., Benchimol, E. I. & Amendoeira, M. R. Toxoplasmic retinochoroiditis: Clinical characteristics and visual outcome in a prospective study. PLoS Negl. Trop. Dis. 10, e0004685 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"82830_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ajo.2008.01.023","volume":"145","author":"GN Holland","year":"2008","unstructured":"Holland, G. N. et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 145, 1007\u20131013 (2008).","journal-title":"Am. J. Ophthalmol."},{"key":"82830_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0002-9394(02)01527-1","volume":"134","author":"C Silveira","year":"2002","unstructured":"Silveira, C. et al. The effect of long-term intermittent trimethoprim\/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 134, 41\u201346 (2002).","journal-title":"Am. J. Ophthalmol."},{"key":"82830_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ajo.2013.12.022","volume":"157","author":"JP Felix","year":"2014","unstructured":"Felix, J. P. et al. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: Randomized controlled clinical trial. Am. J. Ophthalmol. 157, 762-766.e761 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"82830_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajo.2016.08.003","volume":"170","author":"JP Felix","year":"2016","unstructured":"Felix, J. P. et al. Trimethoprim-sulfamethoxazole versus placebo in reducing the risk of toxoplasmic retinochoroiditis recurrences: A three-year follow-up. Am. J. Ophthalmol. 170, 176\u2013182 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"82830_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajo.2019.12.025","volume":"213","author":"JP Felix","year":"2020","unstructured":"Felix, J. P. et al. Long-term results of trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrent Toxoplasma gondii retinochoroiditis. Am. J. Ophthalmol. 213, 195\u2013202 (2020).","journal-title":"Am. J. Ophthalmol."},{"key":"82830_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/09273948.2016.1215471","volume":"26","author":"FB Morais","year":"2018","unstructured":"Morais, F. B., Arantes, T. & Muccioli, C. Current practices in ocular toxoplasmosis: A survey of Brazilian uveitis specialists. Ocul. Immunol. Inflamm. 26, 317\u2013323 (2018).","journal-title":"Ocul. Immunol. Inflamm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82830-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T22:29:24Z","timestamp":1670020164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82830-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82830"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82830-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3137"}}